Philip Morris International Inc（PM）の決算・業績分析

Philip Morris International Inc. (PM) FY2024 Annual Report Analysis

Highlights

Business Overview

Philip Morris International Inc. (PM) operates as a global tobacco company focused on transitioning to smoke-free products, including IQOS heat-not-burn devices, ZYN nicotine pouches, and other alternatives (10-K). The business model relies on selling cigarettes (~170 markets) and smoke-free products, with a strategic emphasis on reducing harm from traditional tobacco (10-K). Key competitive advantages include FDA authorizations for Modified Risk Tobacco Products (MRTP), scientific R&D capabilities, and the 2022 acquisition of Swedish Match (10-K). The company faces risks from regulatory scrutiny, particularly the WHO's 2023 policy recommendations on tobacco product regulation (10-K).

Revenue Analysis

Revenue increased 1.1% YoY to $31.8B (XBRL), driven by growth in smoke-free products. However, operating income declined 5.6% YoY to $12.2B (XBRL), reflecting margin pressures. The 5-year revenue CAGR of 3.5% (XBRL) contrasts with flat operating income growth (0.3% CAGR) and declining net income (-0.2% CAGR). Historical data shows revenue peaked at $35.2B in FY2025 (XBRL), but operating income has trended downward since FY2023.

Profitability Analysis

Gross margin remained strong at 64.1% (XBRL), but operating margin fell to 38.6% (XBRL), down from prior years. Net margin declined to 28.5% (XBRL), reflecting lower profitability. EBITDA of $13.3B (XBRL) represents 42.0% of revenue, indicating robust pre-interest cash generation. The 5-year net income CAGR of -0.2% (XBRL) highlights challenges in sustaining profitability despite revenue growth.

Balance Sheet Analysis

Total assets grew to $65.3B (XBRL) in FY2024, but equity declined to -11.2B (XBRL), resulting in a negative equity ratio of -17.2% (XBRL) and a debt-to-equity ratio of -6.66x (XBRL). Current ratio of 0.75x (XBRL) suggests short-term liquidity constraints. Cash reserves stood at $3.1B (XBRL), though this is offset by significant long-term debt ($42.166B in 2024, $41.243B in 2023) (10-K).

Cash Flow Analysis

Operating cash flow of $10.8B (XBRL) supported $9.7B in free cash flow (FCF) after $1.1B in CapEx (XBRL). Dividends paid totaled $7.8B (XBRL), representing a 86.3% payout ratio (XBRL). Share repurchases amounted to $209M (XBRL), though this was far smaller than dividend disbursements. Investing cash flow was -$15.7B (XBRL), likely reflecting asset acquisitions and R&D investments ($642M in R&D expense) (XBRL).

Working Capital Analysis

Cash conversion cycle (CCC) of 252 days (XBRL) indicates significant working capital inefficiencies. Receivables days were 40 days (XBRL), but inventory days surged to 345 days (XBRL), and payables days were 133 days (XBRL). This suggests challenges in managing inventory turnover and supplier payment terms.

Risks

Outlook

Management guidance emphasizes accelerating the transition to smoke-free products, though historical data shows operating income has declined since FY2023. The 5-year revenue CAGR of 3.5% (XBRL) suggests moderate growth, but profitability metrics remain under pressure. The company faces ongoing regulatory risks, particularly from the WHO's 2023 policy recommendations (10-K).

Historical Time Series